Trials / Unknown
UnknownNCT05374954
Study on Sequential Immunization of Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18 Years Old and Above
Safety and Immunogenicity Study on Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18 Years Old and Above Vaccinated the Prototype Inactivated COVID-19 Vaccine
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 4,200 (actual)
- Sponsor
- China National Biotec Group Company Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This is a randomized, double blind, positive controlled study to evaluate the safety and immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in population aged 18 years old and above who have been vaccinated with 2 or 3 doses of COVID-19 Vaccine (Vero Cell), Inactivated manufactured by Beijing Institute of Biological Products, Co., Ltd.
Detailed description
This is a randomized, double blind, positive controlled study to evaluate the safety and immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in population aged 18 years old and above who have been vaccinated with 2 or 3 doses of COVID-19 Vaccine (Vero Cell), Inactivated manufactured by Beijing Institute of Biological Products, Co., Ltd. According to subject's age (18-59 vs 60 and above), doses of vaccination history ( 2 doses vs 3 doses), and vaccination interval, the subjects will be stratified and assigned randomly to the study groups ( Omicron inactivated COVID-19 Vaccine) or the control groups ( Prototype inactivated COVID-19 Vaccine) in a 2:1 ratio. All subjects will receive single dose or two doses of vaccine with a interval of 28 days. The occurrence of adverse events within 28 days and serious adverse events within 12 months after vaccination will be observed. The serum antibody levels, cellular immune responses will be analyzed at different time points.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Omicron COVID-19 Vaccine (Vero Cell), Inactivated | intramuscular injection in the deltoid muscle |
| BIOLOGICAL | COVID-19 Vaccine (Vero Cell), Inactivated | intramuscular injection in the deltoid muscle |
Timeline
- Start date
- 2022-05-10
- Primary completion
- 2022-09-25
- Completion
- 2023-11-10
- First posted
- 2022-05-16
- Last updated
- 2023-06-18
Locations
10 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05374954. Inclusion in this directory is not an endorsement.